Lilly plans to invest $700 million to boost insulin production

Source: DXY pharmaceutical said on November 19, 2013 that it would invest more than $700 million in Puerto Rico, France, China and the United States to improve its insulin production capacity The company's traditional area has always been insulin therapy, but its drug sales have been plagued by competition from other companies, including Denmark's Novo Nordisk Diabetes is increasingly becoming a difficult battle field in the world According to the data provided by the International Diabetes Federation, the number of diabetic patients is expected to soar to a record 382 million this year Lilly said on November 14 that it will invest US $350 million in China, which has become the world's largest diabetic country, and the number is expected to grow from 98.4 million now to 142 million by 2035 Lilly also said it plans to invest $120 million in France and $245 million in Puerto Rico and Indianapolis, Indiana, to expand its production of insulin APIs and delivery equipment The Indianapolis based company has been cutting costs because some of its best-selling drugs have lost patent protection and are growing more slowly in emerging markets.